RA Outcomes Improved in KURAMA Cohort - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

RA Outcomes Improved in KURAMA Cohort

Ten-year observational data showed lower disease activity and functional disability coinciding with broader use of biologic and targeted synthetic therapies.

  • By

  • Andrea Surnit

  • May 22, 2026

  • 4 min

Share

Objective:

To analyze the long-term outcomes of patients with rheumatoid arthritis (RA) in the KURAMA cohort over a 10-year period.

Key Findings:
  • Include detail about methotrexate use remaining above 60% throughout the study period.
Interpretation:

Remove unsupported conclusions regarding the sensitivity of the Disease Activity Score 28-C-reactive protein.

Limitations:
  • Explicitly mention the lack of generalizability due to the single-center nature of the study.
Conclusion:

Remove unsupported summary statements about the transition of therapeutic strategies.

Original Source(s)

RA Outcomes Improved in KURAMA Cohort

  • by Andrea Surnit

  • May 22, 2026

Related Content

Autoantibodies to Joint-Related Peptides Are Associated With Onset of Rheumatoid Arthritis in Presymptomatic Seronegative Individuals

RA Genetics May Reveal Link to Gum Disease

Analysis of East Asian genetic data found a modest inverse association between rheumatoid arthritis susceptibility and periodontitis risk, though researchers said the findings require confirmation in independent cohorts.

DNA (cytosine-5)-methyltransferase 3A (Dnmt3a) mutations limit normal and autoreactive CD4+ T follicular helper responses and attenuate T cell-driven joint inflammation